These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 34472583)

  • 1. Similar Antibody Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 in Individuals Living Without and With Human Immunodeficiency Virus on Antiretroviral Therapy During the First South African Infection Wave.
    Snyman J; Hwa SH; Krause R; Muema D; Reddy T; Ganga Y; Karim F; Leslie A; Sigal A; Ndung'u T;
    Clin Infect Dis; 2022 Aug; 75(1):e249-e256. PubMed ID: 34472583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant.
    Hwa SH; Snyman J; Bernstein M; Ganga Y; Cele S; Muema D; Tan CW; Khan K; Karim F; Hanekom W; Bernstein L; Kaufmann SHE; Wang LF; Ndung'u T; Sigal A;
    J Infect Dis; 2023 Jan; 227(2):211-220. PubMed ID: 35975942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.
    Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Umviligihozo G; Kalikawe R; Speckmaier S; Moran-Garcia N; Datwani S; Duncan MC; Agafitei O; Ennis S; Young L; Ali H; Ganase B; Omondi FH; Dong W; Toy J; Sereda P; Burns L; Costiniuk CT; Cooper C; Anis AH; Leung V; Holmes DT; DeMarco ML; Simons J; Hedgcock M; Prystajecky N; Lowe CF; Pantophlet R; Romney MG; Barrios R; Guillemi S; Brumme CJ; Montaner JSG; Hull M; Harris M; Niikura M; Brockman MA; Brumme ZL
    J Infect Dis; 2023 Apr; 227(7):838-849. PubMed ID: 35668700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
    Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
    Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 seroprevalence and associated factors among people living with HIV in Sierra Leone.
    Sun W; Song J; Lakoh S; Chen J; Jalloh AT; Sahr F; Sevalie S; Jiba DF; Kamara IF; Xin Y; Ye Z; Ding F; Dai LZ; Wang L; Zheng X; Yang G
    Immun Inflamm Dis; 2024 Jul; 12(7):e1338. PubMed ID: 38990142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination.
    Motsoeneng BM; Manamela NP; Kaldine H; Kgagudi P; Hermanus T; Ayres F; Makhado Z; Moyo-Gwete T; van der Mescht MA; Abdullah F; Boswell MT; Ueckermann V; Rossouw TM; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2023; 14():1231276. PubMed ID: 37600825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
    Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
    Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study).
    Kling KD; Janulis P; Demonbreun AR; Sancilio A; Berzins B; Krueger K; Achenbach C; Price R; Sullivan M; Caputo M; Hockney S; Zembower T; McDade TW; Taiwo B
    Front Immunol; 2022; 13():1048776. PubMed ID: 36700200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy.
    Lapointe HR; Mwimanzi F; Cheung PK; Sang Y; Yaseen F; Speckmaier S; Barad E; Moran-Garcia N; Datwani S; Duncan MC; Kalikawe R; Ennis S; Young L; Ganase B; Omondi FH; Umviligihozo G; Dong W; Toy J; Sereda P; Burns L; Costiniuk CT; Cooper C; Anis AH; Leung V; Holmes D; DeMarco ML; Simons J; Hedgcock M; Prystajecky N; Lowe CF; Romney MG; Barrios R; Guillemi S; Brumme CJ; Montaner JSG; Hull M; Harris M; Niikura M; Brockman MA; Brumme ZL
    AIDS; 2023 Apr; 37(5):709-721. PubMed ID: 36545783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern.
    Lafon E; Jäger M; Bauer A; Reindl M; Bellmann-Weiler R; Wilflingseder D; Lass-Flörl C; Posch W
    J Allergy Clin Immunol; 2022 Apr; 149(4):1242-1252.e12. PubMed ID: 35093484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy.
    Jedicke N; Stankov MV; Cossmann A; Dopfer-Jablonka A; Knuth C; Ahrenstorf G; Ramos GM; Behrens GMN
    HIV Med; 2022 May; 23(5):558-563. PubMed ID: 34725907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological, Virological and Serological Features of Coronavirus Disease 2019 (COVID-19) Cases in People Living With Human Immunodeficiency Virus in Wuhan: A Population-based Cohort Study.
    Huang J; Xie N; Hu X; Yan H; Ding J; Liu P; Ma H; Ruan L; Li G; He N; Wei S; Wang X
    Clin Infect Dis; 2021 Oct; 73(7):e2086-e2094. PubMed ID: 32803216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway.
    Krause R; Snyman J; Shi-Hsia H; Muema D; Karim F; Ganga Y; Ngoepe A; Zungu Y; Gazy I; Bernstein M; Khan K; Mazibuko M; Mthabela N; Ramjit D; ; Limbo O; Jardine J; Sok D; Wilson IA; Hanekom W; Sigal A; Kløverpris H; Ndung'u T; Leslie A
    Elife; 2022 Oct; 11():. PubMed ID: 36300787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
    Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
    Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV.
    Ng'uni TL; Musale V; Nkosi T; Mandolo J; Mvula M; Michelo C; Karim F; Moosa MYS; Khan K; Jambo KC; Hanekom W; Sigal A; Kilembe W; Ndhlovu ZM
    Front Immunol; 2023; 14():1291048. PubMed ID: 38343437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals.
    Zou S; Wu M; Ming F; Wu S; Guo W; Marley G; Xing Z; Zhang Z; Zeng M; Sun C; Zhang J; Tang W; Liang K
    AIDS Res Ther; 2022 Jul; 19(1):33. PubMed ID: 35791004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Similar Nucleocapsid Antibody Levels in People With Well-Controlled Human Immunodeficiency Virus (HIV) and a Comparable Cohort of People Without HIV.
    Verburgh ML; Boyd A; Wit FWNM; Schim van der Loeff MF; van der Valk M; Bakker M; Kootstra NA; van der Hoek L; Reiss P
    J Infect Dis; 2022 Jun; 225(11):1937-1947. PubMed ID: 34929034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Descriptive evaluation of antibody responses to severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in plasma and gingival crevicular fluid in a nursing home cohort-Arkansas, June-August 2020.
    Brown NE; Lyons AK; Schuh AJ; Stumpf MM; Harcourt JL; Tamin A; Rasheed MAU; Mills L; Lester SN; Thornburg NJ; Nguyen K; Costantini V; Vinjé J; Huang JY; Gilbert SE; Gable P; Bollinger S; Sabour S; Beshearse E; Surie D; Biedron C; Gregory CJ; Clemmons NS; Whitaker B; Coughlin MM; Seely KA; Garner K; Gulley T; Haney T; Kothari A; Patil N; Halpin AL; McDonald LC; Kutty PK; Brown AC
    Infect Control Hosp Epidemiol; 2022 Nov; 43(11):1610-1617. PubMed ID: 34802478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.